14-16 November 2018

Boston, MA

Day One
Thursday 15th November, 2018

Day Two
Friday 16th November, 2018

07.50
Registration & Morning Coffee

08.50
Chairperson’s Opening Remarks

The Role of the Gut-Brain Axis in Neurodegenerative Diseases

09.00
MJFF Activities in Understanding the Parkinson’s Disease Microbiome

  • Kuldip Dave Director, Research Programs, Michael J. Fox Foundation

09.30
An Epidemiological Study of the Gut Microbiome in Parkinson’s Disease

  • Natalia Palacios Assistant Professor, Department of Public Health, UMass Lowell

10.00
The Role of rgs10 in the Gut-Brain Inflammatory Axis in Parkinson’s Disease

  • Malu Tansey Professor, Department of Physiology, Emory University School of Medicine

10.30
Morning Refreshments & Speed Networking

Building Robust Preclinical Packages – From Mouse to Mechanism

12.00
Translational Approaches to Help Make Sense of Microbiota-Host Mechanisms

  • Jane Foster Associate Professor, Department of Psychiatry and Behavioural Neurosciences, McMaster University

Synopsis

  • Reverse translation approaches in mice provide insight into how gene-environment interactions influence the microbiome
  • Host-microbe communication is reciprocal and influences brain structure, gene expression of stress-related and plasticity-related genes, stress-reactivity, and behavior
  • Big data and data sharing in a rapidly advancing field

The Role of the Gut-Brain Axis in Neurodevelopmental Diseases

12.30
Short Chain Fatty Acids- Microbial Modulators of Metabolism, Mitochondria and Mind- Implications in Neurodevelopmental Disorders

  • Derrick Macfabe MD, Co-Founder and Director, Kilee Patchell-Evans Autism Research Group

Synopsis

  • Discussing mechanisms derived from translational models and human populations where small molecule metabolites of the host microbiome may effect brain function and behavior
  • How are levels of these small molecules altered in relation to diet, birth practices, microbial populations, antimicrobials, metabolic intermediates and genetic endophenotypes
  • Are there potential therapeutic mechanisms to modulate small molecule metabolite metabolism to treat or prevent neuropsychiatric disease, or develop screening mechanisms for those “at risk” for these conditions

13.00
Lunch & Networking

14.00
Connecting the Gut Microbiota to Diet, Metabolism, Neural Activity and Behaviour to Develop Effective Microbiota- Based Treatments for Epilepsy and Improved Brain Health

  • Chris Reyes Co-Founder & Chief Scientific Officer, Bloom Science

14.30
Critical Roles for Microbiota-Mediated Regulation of the Immune System in a Prenatal Immune Activation Model of Autism

  • John Lukens Assistant Professor, University of Virginia School of Medicine

Synopsis

  • Autism has been recently associated with dysregulated immune responses and altered microbiota composition
  • Outlining a new study reporting the critical role for prenatal microbiota in the development of behavioural abnormalities in a murine model of autism
  • Discussing results that show the microbiota landscape can influence neurodevelopmental disease pathogenesis

15.00
Microbiomes of Autism Spectrum Disorder Patients Induce Behavioral Deficits in Mice

  • Gil Sharon Postdoctoral Scholar in Biology. Mazmanian Lab, California Institute of Technology

Synopsis

  • ASD fecal Microbiomes elicit behavioral deficits in colonized C57Bl/6J mice.
  • Colnization by ASD microbiomes changes the fecal and serum metabolome
  • Specific metabolites increased in control samples can prevent behavioral deficits in the BTBR mouse model of ASD

15.30
Afternoon Refreshments & Networking

Clinical Trial Design & Development for the Microbiome Gut-Brain Axis

16.00
Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder

Synopsis

  • Introducing the growing evidence linking the intestinal microbiota with the CNS in psychiatric illnesses
  • Sharing a new clinical study to assess the effectiveness of targeting the GBA through FMT, to treat bipolar depression
  • Discussing key considerations within clinical study design and objectives within a breakthrough area

16.30
Searching the Intestinal Environment for Clues to the Etiopathogenesis of Parkinson’s Disease

  • Kathleen Shannon Detling Professor & Chair, Neurology, University of Wisconsin School of Medicine and Public Health

Synopsis

  • Epidemiological and clinicalpathological studies in Parkinson’s disease lend credence to the concept of gastrointestinal dysfunction as a driver of pathology in the disease
  • 11 Published studies suggest microbiome changes in early and advanced Parkinson’s disease as well as in the Parkinson’s prodrome
  • Preclinical evidence supports a role of dysbiosis in Parkinson’s disease

17.00
Panel Discussion: Conducting Clinical Trials in the Gut-Brain Axis: Challenges and Opportunities

  • Valerie Taylor Psychiatrist-in-Chief, Women's College Hospital
  • Kathleen Shannon Detling Professor & Chair, Neurology, University of Wisconsin School of Medicine and Public Health
  • Felice Jacka Professor, School of Medicine, Deakin University

17.40
Chairperson Closing Remarks

17.50
Close of Conference Day One, Scientific Poster Session and Evening Drink’s Reception Hosted by the Microbiome Movement